Azitra, Inc. (NYSEAMERICAN:AZTR – Get Free Report) shares dropped 5.1% during mid-day trading on Thursday . The stock traded as low as $0.18 and last traded at $0.19. Approximately 607,320 shares were traded during mid-day trading, an increase of 18% from the average daily volume of 513,998 shares. The stock had previously closed at $0.20.
Azitra Stock Up 2.7 %
The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.58 and a current ratio of 1.58.
Insider Buying and Selling
In related news, CEO Francisco D. Salva acquired 333,300 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The stock was acquired at an average cost of $0.30 per share, with a total value of $99,990.00. Following the completion of the purchase, the chief executive officer now directly owns 338,300 shares in the company, valued at $101,490. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders purchased a total of 399,200 shares of company stock valued at $115,476 over the last three months.
Institutional Inflows and Outflows
Azitra Company Profile
Azitra, Inc, a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S.
Featured Stories
- Five stocks we like better than Azitra
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MarketBeat Week in Review – 4/15 – 4/19
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Comprehensive Analysis of PayPal Stock
- Using the MarketBeat Stock Split Calculator
- Intuitive Surgical Stock Can Trend Much Higher This Year
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.